Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | F13A1 | P00488 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | THPO | P40225 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA3 | P07451 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499241 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL11754616 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL8499397 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL4256739 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL16269067 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL21794160 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL21799619 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL21799712 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL21799791 | 1.00 | TSHR (0.65) | TSHRCA12F13A1CA2CYP1A2 | |
| SCHEMBL309583 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-12030985-B2 | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | YALE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-116425639-B | Preparation method of plant extract containing spermidine | 汤臣倍健股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11814464-B2 | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | YALE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230293448-A1 | NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODS | YALE UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11735413-B2 | Precursors and flowable CVD methods for making low-k films to fill surface features | VERSUM MATERIALS US, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230257511-A1 | EPOXY-AMINE ADDUCT | EVONIK OPERATIONS GMBH (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230233693-A1 | POLY(AMINE-CO-ESTER) POLYMERS WITH MODIFIED END GROUPS AND ENHANCED PULMONARY DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-27 | — | — | US | disclosed |
| CN-116425639-A | Preparation method of plant extract containing spermidine | 汤臣倍健股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-0658111-B1 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS | CAMBRIDGE BIOTECH CORP (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0841932-A4 | DRUG DELIVERY ENHANCEMENT VIA MODIFIED SAPONINS | AQUILA BIOPHARM INC (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0841932-A1 | DRUG DELIVERY ENHANCEMENT VIA MODIFIED SAPONINS | Aquila Biopharmaceuticals, Inc. (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5650398-A | PLANT EXTRACTS AND DRUG DELIVERY | CAMBRIDGE BIOTECH CORPORATION (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996038161-A1 | DRUG DELIVERY ENHANCEMENT VIA MODIFIED SAPONINS | AQUILA BIOPHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0658111-A4 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS. | CAMBRIDGE BIOTECH CORP (US) | 1996-02-07 | — | — | EP | disclosed |
| US-5443829-A | For enhancing delivery of drugs across mucous membranes of animals | CAMBRIDGE BIOTECH CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0658111-A1 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS | CAMBRIDGE BIOTECH CORPORATION (US) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994001118-A1 | METHODS FOR ENHANCING DRUG DELIVERY WITH MODIFIED SAPONINS | CAMBRIDGE BIOTECH CORPORATION (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5273965-A | A reduced and hydrolyzed saponin from a Quillaja saponaria extract | CAMBRIDGE BIOTECH CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233693-A1 | POLY(AMINE-CO-ESTER) POLYMERS WITH MODIFIED END GROUPS AND ENHANCED PULMONARY DELIVERY | POLM, PARG, PUF60 | TSHR 3242/4885CA12 2957/4885F13A1 135/4885 |
| US-12030985-B2 | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | POLM, PARG, PARN | TSHR 2941/4885CA12 2304/4885F13A1 115/4885 |
| US-20230293448-A1 | NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODS | CD14, PARN, RNGTT | TSHR 4299/4885CA12 2086/4885F13A1 1519/4885 |
| US-11814464-B2 | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | POLM, PARG, PARN | TSHR 2941/4885CA12 2304/4885F13A1 115/4885 |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | TSHR 4123/4885CA12 4469/4885F13A1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.